Skip to content

    Alembic Pharma

    APLLTDGood
    Healthcare·7 Nov 2024
    Management Summary

    Alembic Pharma delivered a mixed performance in Q2 FY25, characterized by strong volume growth in the US and robust performance in the Rest of World (ROW) and Animal Health segments, offset by a sharp decline in the API business. Management is highly optimistic about a 'much stronger' H2, banking on a back-ended launch pipeline of ~10 products in the US and normalized supply chains in ROW. While India's acute segment faced headwinds from a delayed monsoon, the specialty portfolio remains on a steady growth trajectory.

    Highlights

    8
    • Total revenue grew 3% YoY to ₹1,648 crores, driven by US volume and ROW growth.

    • EBITDA increased 18% YoY to ₹257 crores, with margins at 15.6% of sales.

    • Net profit grew 12% YoY to ₹153 crores; EPS stood at ₹7.79 per share.

    • US Generics revenue grew 5% to ₹467 crores, supported by 25% volume growth despite price erosion.

    • India branded business grew 6% to ₹609 crores, with specialty therapies showing high single to double-digit growth.

    • API business saw a significant 15% degrowth due to price erosion and loss of key accounts.

    • R&D spend was ₹133 crores (8% of sales), with FY25 guidance narrowed to ₹500-520 crores.

    • Gross borrowings spiked to ₹995 crores due to dividend outflows and inventory build-up for H2 launches.

    Concerns

    1
    • US Price Erosion

    What Changed2

    vs Q4 FY25

    Guidance items7 → 6 (-1)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹1,648 Cr+3%YoY
    2. 02EBITDA₹257 Cr+18%YoY
    3. 03EBITDA Margin15.6%
    4. 04Net Profit₹153 Cr+12%YoY
    5. 05EPS₹7.79+12%YoY

    Segment breakdown

    India Branded Business
    ₹609 Cr Revenue6% Growth
    US Generics
    ₹467 Cr Revenue5% Growth25% Volume Growth
    Ex-US Generics (ROW)
    18% Growth
    API Business
    -15% Growth
    Animal Health
    20% Growth
    List

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Ex-US Generics (ROW) Growth
    15% to 20%
    High
    Revenue
    India Business Growth
    high single digit
    Medium
    Volume
    US Product Launches
    10
    High
    Margin
    Gross Margin Range
    72% ±
    Medium
    Other
    R&D Spend
    ₹500-520 crores
    High
    Debt
    Borrowing Level
    much lower
    Medium

    Risks & concerns

    6
    RiskSeverity

    US Price Erosion

    Erosion is in the high single digits to low double digits, requiring high volume growth and new launches to offset.Management acknowledged

    high

    API Pricing and Competitive Pressure

    Aggressive pricing from China and loss of key accounts led to a 15% segment decline.Both acknowledged

    medium

    Rising Debt and Working Capital

    Borrowings rose to ₹995 crores due to inventory build-up for H2 launches and dividend payments.Analyst acknowledged

    medium

    Lag in R&D Filings

    A temporary lag in filings (only 4 in H1) due to a shift toward complex generics and previous cost-reduction measures.Management acknowledged

    low

    Areas of Evasion(2)

    • Specific initiatives for domestic growth beyond 'productivity'
    • Specific dates for settlement-based product launches (Bosutinib/Olaparib)

    Q&A highlights

    3

    “Growth not driven by increase in number of field force. It's more driven by better productivity out of our existing team... I do not like to get into details at this moment.”

    Management was defensive regarding specific growth initiatives for FY26/27, emphasizing productivity over headcount expansion.

    asked by Rashmi S., Dolat Capital

    2 min read5 chapters

    Detailed Narrative

    01

    US Generics: Volume Overcomes Value Erosion

    The US business grew 5% to ₹467 crores, a result that masks a significant 25% surge in volumes. This volume growth was necessary to offset persistent price erosion, which management characterized as being in the high single to low double digits. With 8 launches in Q2 and another 10 planned for H2, management expects market share gains to accelerate as these products ramp up. The oncology facility also successfully cleared a surprise US FDA inspection with zero observations (no Form 483).

    02

    India Branded: Specialty Resilience Amidst Acute Headwinds

    India revenue grew 6% to ₹609 crores, led by strong performance in specialty segments like Antidiabetic (18%), Ophthalmology (13%), and Cardiology (11%). However, the Acute segment, particularly the flagship brand Azithral, faced a high base and a slow start to the monsoon season, leading to flat performance. Management expects a recovery to high single-digit growth in H2, driven by improved doctor footfalls and better productivity from the existing field force rather than headcount expansion.

    03

    API Segment: Structural Shifts and Competitive Pressures

    The API business was a major drag this quarter, declining 15% YoY. Management attributed this to a 'fundamental business shift' where some partners moved to alternate sources for better pricing. Increased aggression from Chinese suppliers and general price erosion in the segment have impacted margins. While management expects H2 to remain at these lower levels, they anticipate a recovery starting in FY26 as they work to regain lost accounts and leverage their high-margin API portfolio.

    04

    Strategic Pivot to Peptides and GLP-1s

    Alembic is making significant investments in the peptide and GLP-1 space, including a new peptide block at their existing API facility. They have confirmed plans to target Semaglutide and Tirzepatide with in-house manufacturing capabilities developed over the last 4-5 years. While they admit they will be 'a little late' and not part of the first generic wave for Semaglutide, they view the expanding indications for GLP-1s as a massive long-term opportunity that justifies current capex.

    05

    Financial Outlook: Inventory Build-up and Debt Management

    Gross borrowings rose to ₹995 crores, up from ₹784 crores a year ago, primarily due to a ₹200+ crore dividend payout and strategic inventory build-up to support H2 launches. Management expects working capital to normalize and debt to reduce significantly by the end of the fiscal year. R&D guidance was slightly moderated to ₹500-520 crores as the company focuses on more complex filings, which has caused a temporary lag in the number of ANDA submissions.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.